Transkaryotic(tktx) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Transkaryotic(tktx)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: trevor john wilkinson who started this subject	10/5/2000 4:07:52 PM
From: Souze	of 122

PHILADELPHIA, Oct 5, 2000 /PRNewswire via COMTEX/ -- Transkaryotic Therapies, Inc. (Nasdaq: TKTX chart, msgs) today announced positive pivotal clinical results of its investigational enzyme replacement therapy, Replagal(TM) (agalsidase alfa), for the treatment of Fabry disease. The data, presented today at the 50th Annual Meeting of the American Society of Human Genetics in Philadelphia, suggest that treatment with Replagal(TM) has broad clinical effects in patients with Fabry disease. ......... siliconinvestor.com Story was also carried by Dow Jones.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next